Cullinan Therapeutics Inc (CGEM)
NASDAQ:CGEM
Want to see CGEM full AI Analyst Report?
CGEM Stock Chart & Stats
$15.06
-$0.28(-2.38%)
At close: 4:00 PM EST
$15.06
-$0.28(-2.38%)
Day’s Range― - ―
52-Week Range$5.68 - $16.74
Previous CloseN/A
Volume73.34K
Average Volume (3M)1.16M
Market Cap
$841.98M
Enterprise Value$937.67M
Total Cash (Recent Filing)$351.88M
Total Debt (Recent Filing)$2.38M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 06, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding61,458,046
10 Day Avg. Volume1,269,402
30 Day Avg. Volume1,157,780
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.48
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.87K
Enterprise Value/Ebitda-4.25
Forecast
1Y Price Target
$33.56Price Target Upside122.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.06
Revenue Forecast (FY)$19.68M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthVery low debt reduces refinancing and interest-rate risk, giving management durable financial flexibility to fund clinical programs, pursue partnerships, or time non-dilutive financing. Over the next 2–6 months this buffer supports continued R&D and optionality without immediate solvency pressure.
Promising CLN-978 Early Clinical ReadoutsRobust early efficacy and tissue B‑cell depletion across SLE and RA are a structural positive: they validate mechanism, expand addressable markets beyond oncology, and materially improve the asset's partnership and commercialization prospects if signals hold into later-stage trials.
Diversified Pipeline & Collaborative R&DA diversified development-stage pipeline plus collaborative R&D reduces single-asset concentration risk and leverages external expertise and milestone financing. This model provides durable strategic options—licensing, partnerships, or co-development—that can stabilize funding and accelerate go-to-market paths.
Bears Say
High Cash Burn / Large LossesSustained, large cash burn creates structural funding requirements and increases dilution or financing risk. Over a 2–6 month horizon the company remains dependent on external capital to sustain trials, limiting strategic flexibility and raising execution risk if capital markets tighten.
Minimal Revenue / Pre-commercial ProfileLack of recurring product revenue means future cash flows hinge on trial success, partnerships, or milestone payments. This structural dependence on binary development outcomes amplifies risk and reduces visibility into sustainable earnings or internal funding capacity over the medium term.
Declining Equity & Negative ROEMaterial decline in equity and deeply negative ROE indicate capital erosion from operating losses and likely dilution. This undermines long-term shareholder value, may raise cost of capital, and constrains non-dilutive financing options vital for supporting multiple development programs.
Cullinan Management News
CGEM FAQ
What was Cullinan Therapeutics Inc’s price range in the past 12 months?
Cullinan Therapeutics Inc lowest stock price was $5.68 and its highest was $16.74 in the past 12 months.
What is Cullinan Therapeutics Inc’s market cap?
Cullinan Therapeutics Inc’s market cap is $841.98M.
When is Cullinan Therapeutics Inc’s upcoming earnings report date?
Cullinan Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 51 days.
How were Cullinan Therapeutics Inc’s earnings last quarter?
Cullinan Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.836 by $0.086.
Is Cullinan Therapeutics Inc overvalued?
According to Wall Street analysts Cullinan Therapeutics Inc’s price is currently Undervalued.
Does Cullinan Therapeutics Inc pay dividends?
Cullinan Therapeutics Inc does not currently pay dividends.
What is Cullinan Therapeutics Inc’s EPS estimate?
Cullinan Therapeutics Inc’s EPS estimate is -0.8.
How many shares outstanding does Cullinan Therapeutics Inc have?
Cullinan Therapeutics Inc has 61,458,046 shares outstanding.
What happened to Cullinan Therapeutics Inc’s price movement after its last earnings report?
Cullinan Therapeutics Inc reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.836. Following the earnings report the stock price went down -1.801%.
Which hedge fund is a major shareholder of Cullinan Therapeutics Inc?
Currently, no hedge funds are holding shares in CGEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cullinan Management Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.56 (122.81% Upside)
$33.56 (122.81% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 82.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.07%
12-Months-Change
Fundamentals
Return on Equity
-51.45%
Trailing 12-Months
Asset Growth
-30.48%
Trailing 12-Months
Company Description
Cullinan Therapeutics Inc
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
CGEM Stock 12 Month Forecast
Average Price Target
$33.56
▲(122.81% Upside)
Technical Analysis
Ownership Overview
16.50% Insiders
8.95% Mutual Funds
23.83% Other Institutional Investors
34.63% Public Companies and Individual Investors